[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_8749 

# __Low percentage of individuals infected, with an attack rate on average of 4.9%.__

## Articles mentionning the risk

* [Flaxman_report_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_470.md)

## Mitigations of this risk

* [Continue control measures, develop and implement vaccination strategies.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_10642.md)

## Name of the risk

The population is not close to herd immunity, leading to the potential for rapid spread of the virus if interventions are lifted.

## People affected by this risk

* [General population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_68.md)
* [Healthcare workers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_9.md)
* [Public health agencies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_222.md)

## Stakeholders who can mitigate this risk

* [Government](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_73.md)
* [Health authorities](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_394.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Continued monitoring and testing](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_826.md)
* [Vaccines](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_10443.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Failure to implement preventive measures](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_12.md)

